214 related articles for article (PubMed ID: 30719824)
1. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
Ogihara K; Kikuchi E; Okazaki S; Hagiwara M; Takeda T; Matsumoto K; Kosaka T; Mikami S; Saya H; Oya M
Cancer Sci; 2019 Apr; 110(4):1431-1441. PubMed ID: 30719824
[TBL] [Abstract][Full Text] [Related]
2. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Wada F; Koga H; Akiba J; Niizeki T; Iwamoto H; Ikezono Y; Nakamura T; Abe M; Masuda A; Sakaue T; Tanaka T; Kakuma T; Yano H; Torimura T
Cancer Sci; 2018 Sep; 109(9):2801-2810. PubMed ID: 29981246
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
4. Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
Takayama T; Kubo T; Morikawa A; Morita T; Nagano O; Saya H
Med Oncol; 2016 May; 33(5):45. PubMed ID: 27044355
[TBL] [Abstract][Full Text] [Related]
5. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
Haryu S; Saito R; Jia W; Shoji T; Mano Y; Sato A; Kanamori M; Sonoda Y; Sampetrean O; Saya H; Tominaga T
J Neurooncol; 2018 Jan; 136(1):23-31. PubMed ID: 28929335
[TBL] [Abstract][Full Text] [Related]
7. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
Hagiwara M; Kikuchi E; Tanaka N; Kosaka T; Mikami S; Saya H; Oya M
BMC Cancer; 2018 Jan; 18(1):113. PubMed ID: 29385995
[TBL] [Abstract][Full Text] [Related]
8. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer.
Seishima R; Okabayashi K; Nagano O; Hasegawa H; Tsuruta M; Shimoda M; Kameyama K; Saya H; Kitagawa Y
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):487-93. PubMed ID: 26775891
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalation study for the targeting of CD44v
Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
[TBL] [Abstract][Full Text] [Related]
10. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
11. Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models.
Thanee M; Padthaisong S; Suksawat M; Dokduang H; Phetcharaburanin J; Klanrit P; Titapun A; Namwat N; Wangwiwatsin A; Sa-Ngiamwibool P; Khuntikeo N; Saya H; Loilome W
Cancer Metab; 2021 Mar; 9(1):11. PubMed ID: 33726850
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
Shitara K; Doi T; Nagano O; Fukutani M; Hasegawa H; Nomura S; Sato A; Kuwata T; Asai K; Einaga Y; Tsuchihashi K; Suina K; Maeda Y; Saya H; Ohtsu A
Gastric Cancer; 2017 Nov; 20(6):1004-1009. PubMed ID: 28466360
[TBL] [Abstract][Full Text] [Related]
14. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
[TBL] [Abstract][Full Text] [Related]
15. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
16. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.
Thanee M; Loilome W; Techasen A; Sugihara E; Okazaki S; Abe S; Ueda S; Masuko T; Namwat N; Khuntikeo N; Titapun A; Pairojkul C; Saya H; Yongvanit P
Cancer Sci; 2016 Jul; 107(7):991-1000. PubMed ID: 27176078
[TBL] [Abstract][Full Text] [Related]
17. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
Hagiwara M; Kikuchi E; Kosaka T; Mikami S; Saya H; Oya M
Urol Oncol; 2016 Aug; 34(8):337.e19-26. PubMed ID: 27133224
[TBL] [Abstract][Full Text] [Related]
18. CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.
Kakehashi A; Ishii N; Sugihara E; Gi M; Saya H; Wanibuchi H
Cancer Sci; 2016 May; 107(5):609-18. PubMed ID: 26882440
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
Wu CT; Lin WY; Chen WC; Chen MF
Ann Surg Oncol; 2018 Nov; 25(12):3518-3526. PubMed ID: 30128900
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
